Soluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1838 views | HTML 2703 views | ?
Shang-Yi Huang1,*, Hsiu-Hsia Lin1,*, Chung-Wu Lin2, Chi-Cheng Li3, Ming Yao1, Jih-Luh Tang1,3, Hsin-An Hou1, Woei Tsay1, Sheng-Je Chou1, Chieh-Lung Cheng1, Hwei-Fang Tien1
1Department of Internal Medicine, National Taiwan University, Medical College and Hospital, Taipei, Taiwan
2Department of Pathology, National Taiwan University, Medical College and Hospital, Taipei, Taiwan
3Tai-Cheng Stem Cell Therapy Center, National Taiwan University, Taipei, Taiwan
*These authors have contributed equally to this work
Shang-Yi Huang, email: [email protected]
Keywords: soluble PD-L1, bone marrow plasma, multiple myeloma, autologous transplantation, prognosis
Received: April 25, 2016 Accepted: August 11, 2016 Published: August 23, 2016
Autologous hematopoietic stem cell transplantation (AuHSCT) is standard in treating eligible multiple myeloma (MM) patients. However, the outcome after treatment is highly variable. We used ELISA to analyze the levels of soluble PD-L1 (suPD-L1) in bone marrow (BM) plasma from 61 patients with MM at 100 days after AuHSCT. Patients were classified into high (H) and normal-to-low (NL) groups depending on their suPD-L1 levels. Among patients who had a very good partial response (VGPR) or better after AuHSCT, those in the H-group had a shorter response period (RpSCT) as well as shorter overall survival (OS) than those in the NL-group. Multivariate analyses confirmed that a high suPD-L1 level and high-risk cytogenetic abnormalities are independent factors for RpSCT. Our data suggest that suPD-L1 in the BM plasma of MM patients who have VGPR or better after AuHSCT could be used as a biomarker to predict outcome.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.